NASDAQ:BCTXW

BriaCell Therapeutics (BCTXW) Stock Price, News & Analysis

$0.94
0.00 (0.00%)
(As of 04/26/2024 ET)
Today's Range
$0.87
$1.03
50-Day Range
$0.90
$1.87
52-Week Range
$0.71
$3.30
Volume
111,068 shs
Average Volume
24,126 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BCTXW stock logo

About BriaCell Therapeutics Stock (NASDAQ:BCTXW)

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

BCTXW Stock Price History

BCTXW Stock News Headlines

Get Rich Quick With These 3 Penny Stocks to Buy Now
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
He Is Giving Away Bitcoin
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
See More Headlines
Receive BCTXW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BCTXW
Web
N/A
Fax
N/A
Employees
16
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. William V. Williams M.D. (Age 69)
    CEO, President & Director
    Comp: $785.3k
  • Mr. Gadi Levin B.Com. (Age 51)
    C.A., CPA, M.B.A., CFO & Corporate Secretary
    Comp: $304.46k
  • Dr. Miguel A. Lopez-Lago Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $298.9k
  • Dr. Giuseppe Del Priore M.D. (Age 62)
    M.P.H., MPH, Chief Medical Officer
    Comp: $492.5k
  • Dr. Charles Louis Wiseman FACP (Age 78)
    M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board
    Comp: $241.14k

BCTXW Stock Analysis - Frequently Asked Questions

How have BCTXW shares performed in 2024?

BriaCell Therapeutics' stock was trading at $2.50 at the start of the year. Since then, BCTXW stock has decreased by 62.5% and is now trading at $0.9375.
View the best growth stocks for 2024 here
.

Are investors shorting BriaCell Therapeutics?

BriaCell Therapeutics saw a decline in short interest in March. As of March 31st, there was short interest totaling 600 shares, a decline of 81.3% from the March 15th total of 3,200 shares. Based on an average daily volume of 19,500 shares, the short-interest ratio is presently 0.0 days.
View BriaCell Therapeutics' Short Interest
.

How do I buy shares of BriaCell Therapeutics?

Shares of BCTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCTXW) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners